Pioneering the Next Generation of
CAR-T Cell Therapies

Gracell is developing cell therapy that deliver fast,
deep and durable responses for cancer and autoimmune disease patients

Learn More

Our Mission

We are a global clinical-stage biopharmaceutical company dedicated to discovering and developing innovative and highly efficacious cell therapy to address major industry challenges and fulfill unmet medical needs in the treatment of cancer and autoimmune disease. We aim to disrupt conventional approaches to CAR-T cell therapies with our pioneering FasTCAR and TruUCAR technology platforms and SMART CART^TM technology module.

FasTCART ^™

Our autologous platform producing CAR-T cell therapies that utilize next-day manufacturing to deliver younger, less exhausted T cells with enhanced activities.

TruUCART ^™

Our allogeneic platform generating CAR-T cell therapies that are readily available off-the-shelf at lower cost for a broad patient base.

SMART CART ^™

Our 2^nd generation enhanced CAR-T molecule that tackles the multiple challenges in treating solid tumors.

Pipeline

We are developing a rich clinical-stage pipeline to unlock the long-held promise of CAR-T cell therapies.

Latest News

Feb 22, 2024

Gracell Biotechnologies Acquisition Completed

Feb 20, 2024

Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement

Jan 29, 2024

Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma

Pioneering the Next Generation of CAR-T Cell Therapies